ST未名: 山东未名生物医药股份有限公司2025年股票期权激励计划（草案）

Core Viewpoint - Shandong Weiming Biological Pharmaceutical Co., Ltd. has proposed a stock option incentive plan for 2025, aiming to enhance corporate governance and align the interests of shareholders, the company, and employees [1][8]. Summary by Sections Incentive Plan Overview - The 2025 stock option incentive plan involves granting a total of 46 million stock options, representing 6.97% of the company's total share capital of 659,735,586 shares [2][13]. - The plan is designed to motivate 154 individuals, including directors, senior management, and key technical/business personnel, excluding independent directors [2][11]. Stock Option Details - Each stock option allows the purchase of one share at a price of 7.39 RMB, with adjustments possible in case of capital changes [2][18]. - The plan's validity extends up to 44 months from the date of authorization [3][7]. Conditions for Implementation - The plan requires approval from the shareholders' meeting and must be executed within 60 days post-approval [5][33]. - The company commits not to provide loans or guarantees for any participant in the incentive plan [4][11]. Performance Assessment - The performance assessment for the stock options will be based on company-level and individual-level criteria, with specific growth targets set for revenue and net profit [20][21]. - The company aims for a revenue growth rate of at least 5% for the first exercise period and 10% for the second [20][21]. Adjustments and Accounting - Adjustments to the number of stock options and exercise prices will be made in response to corporate actions such as stock splits or dividends [25][26]. - The fair value of the stock options will be calculated using the Black-Scholes model, with specific parameters outlined for valuation [27][28]. Financial Impact - The implementation of the incentive plan is expected to affect the company's future net profit and return on equity, with estimated costs associated with the stock options detailed [29][30].